Cesca Therapeutics Inc. to Present at the 8th Spring Meeting of the International Society for BioProcess Technology (ISBiotech)

RANCHO CORDOVA, Calif., Feb. 28, 2018 -- Cesca Therapeutics Inc. (“Cesca”) (NASDAQ:KOOL) a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Phil Coelho, chief technology officer of ThermoGenesis Corp., Cesca’s device division, will be presenting at the 8^th Spring Meeting of the International Society for BioProcess Technology (ISBiotech). ISBiotech is being held March 5-7, 2018 at the Hilton Norfolk The Main Hotel in Norfolk, Virginia.

Mr. Coelho’s presentation, “Automated, Closed System Manufacturing of CAR-T Cells,” is scheduled to take place on Wednesday, March 7 from 1:30-2:15pm EST.

For more information about the ISBiotech Spring Meeting, go to: www.isbiotech.org

About Cesca Therapeutics Inc.        
Cesca Therapeutics develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis, provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress platform that addresses the critical unmet need for better cellular manufacturing and controls (CMC) for the emerging CAR-T immunotherapy market. Cesca is an affiliated company of China-based Boyalife Group.

Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
[email protected] 

Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
[email protected]